Literature DB >> 15136659

Comparison of HIV infection risk behaviors among injection drug users from East and West Coast US cities.

Richard S Garfein1, Edgar R Monterroso, Tony C Tong, David Vlahov, Don C Des Jarlais, Peter Selwyn, Peter R Kerndt, Carl Word, M Daniel Fernando, Lawrence J Ouellet, Scott D Holmberg.   

Abstract

This study assessed whether behavioral differences explained higher human immunodeficiency virus (HIV) seroprevalence among injection drug users (IDUs) in three East Coast versus two West Coast cities in the United States. Sociodemographic, sexual, and injecting information were collected during semiannual face-to-face interviews. Baseline data from New York City; Baltimore, Maryland; and New Haven, Connecticut, were compared with data from Los Angeles, California, and San Jose, California. Among 1,528 East Coast and 1,149 West Coast participants, HIV sero-prevalence was 21.5% and 2.3%, respectively (odds ratio [OR] 11.9; 95% confidence interval [CI] 7.9-17.8). HIV risk behaviors were common among IDUs on both coasts, and several were more common among West Coast participants. Adjusting for potential risk factors, East (vs. West) Coast of residence remained highly associated with HIV status (adjusted OR 12.14; 95% CI 7.36-20.00). Differences in HIV sero-prevalence between East and West Coast cities did not reflect self-reported injection or sexual risk behavior differences. This suggests that other factors must be considered, such as the probability of having HIV-infected injection or sexual partners. Prevention efforts are needed on the West Coast to decrease HIV-associated risk behaviors among IDUs, and further efforts are also needed to reduce HIV incidence on the East Coast.

Entities:  

Mesh:

Year:  2004        PMID: 15136659      PMCID: PMC3456450          DOI: 10.1093/jurban/jth112

Source DB:  PubMed          Journal:  J Urban Health        ISSN: 1099-3460            Impact factor:   3.671


  11 in total

1.  HIV-1 transmission in injection paraphernalia: heating drug solutions may inactivate HIV-1.

Authors:  M C Clatts; R Heimer; N Abdala; L A Goldsamt; J L Sotheran; K T Anderson; T M Gallo; L D Hoffer; P A Luciano; T Kyriakides
Journal:  J Acquir Immune Defic Syndr       Date:  1999-10-01       Impact factor: 3.731

Review 2.  The epidemiology of HIV infection and AIDS in Thailand.

Authors:  B G Weniger; K Limpakarnjanarat; K Ungchusak; S Thanprasertsuk; K Choopanya; S Vanichseni; T Uneklabh; P Thongcharoen; C Wasi
Journal:  AIDS       Date:  1991       Impact factor: 4.177

3.  HIV seroprevalence among street-recruited injection drug and crack cocaine users in 16 US municipalities.

Authors:  A H Kral; R N Bluthenthal; R E Booth; J K Watters
Journal:  Am J Public Health       Date:  1998-01       Impact factor: 9.308

4.  High-risk personal networks and syringe sharing as risk factors for HIV infection among new drug injectors.

Authors:  A Neaigus; S R Friedman; B Jose; M F Goldstein; R Curtis; G Ildefonso; D C Des Jarlais
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-04-15

Review 5.  Epidemiology of HIV and AIDS in India.

Authors:  M K Jain; T J John; G T Keusch
Journal:  AIDS       Date:  1994       Impact factor: 4.177

6.  Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities.

Authors:  Christopher S Murrill; Howard Weeks; Brian C Castrucci; Hillard S Weinstock; Beth P Bell; Catherine Spruill; Marta Gwinn
Journal:  Am J Public Health       Date:  2002-03       Impact factor: 9.308

7.  Prevention of HIV infection in street-recruited injection drug users. The Collaborative Injection Drug User Study (CIDUS).

Authors:  E R Monterroso; M E Hamburger; D Vlahov; D C Des Jarlais; L J Ouellet; F L Altice; R H Byers; P R Kerndt; J K Watters; B P Bowser; M D Fernando; S D Holmberg
Journal:  J Acquir Immune Defic Syndr       Date:  2000-09-01       Impact factor: 3.731

Review 8.  The estimated prevalence and incidence of HIV in 96 large US metropolitan areas.

Authors:  S D Holmberg
Journal:  Am J Public Health       Date:  1996-05       Impact factor: 9.308

9.  Estimating AIDS infection rates in the San Francisco cohort.

Authors:  R H Byers; W M Morgan; W W Darrow; L Doll; H W Jaffe; G Rutherford; N Hessol; P M O'Malley
Journal:  AIDS       Date:  1988-06       Impact factor: 4.177

10.  The San Francisco Men's Health Study: III. Reduction in human immunodeficiency virus transmission among homosexual/bisexual men, 1982-86.

Authors:  W Winkelstein; M Samuel; N S Padian; J A Wiley; W Lang; R E Anderson; J A Levy
Journal:  Am J Public Health       Date:  1987-06       Impact factor: 9.308

View more
  12 in total

1.  Use of Medicaid data to explore community characteristics associated with HIV prevalence among beneficiaries with schizophrenia.

Authors:  James Walkup; Ayse Akincigil; Donald R Hoover; Michele J Siegel; Shahla Amin; Stephen Crystal
Journal:  Public Health Rep       Date:  2011 Sep-Oct       Impact factor: 2.792

2.  "Vivo para consumirla y la consumo para vivir" ["I live to inject and inject to live"]: high-risk injection behaviors in Tijuana, Mexico.

Authors:  Steffanie A Strathdee; Wendy Davila Fraga; Patricia Case; Michelle Firestone; Kimberly C Brouwer; Saida Gracia Perez; Carlos Magis; Miguel Angel Fraga
Journal:  J Urban Health       Date:  2005-09       Impact factor: 3.671

Review 3.  Historical trends in the production and consumption of illicit drugs in Mexico: implications for the prevention of blood borne infections.

Authors:  Jesus Bucardo; Kimberly C Brouwer; Carlos Magis-Rodríguez; Rebeca Ramos; Miguel Fraga; Saida G Perez; Thomas L Patterson; Steffanie A Strathdee
Journal:  Drug Alcohol Depend       Date:  2005-04-01       Impact factor: 4.492

4.  Injecting and HIV prevalence among young heroin users in three Spanish cities and their association with the delayed implementation of harm reduction programmes.

Authors:  Luis de la Fuente; María José Bravo; Carlos Toro; M Teresa Brugal; Gregorio Barrio; Vicente Soriano; Fernando Vallejo; Rosario Ballesta
Journal:  J Epidemiol Community Health       Date:  2006-06       Impact factor: 3.710

5.  Discrete-trials heroin self-administration produces sensitization to the reinforcing effects of cocaine in rats.

Authors:  Sara J Ward; Christopher Läck; Drake Morgan; David C S Roberts
Journal:  Psychopharmacology (Berl)       Date:  2006-01-14       Impact factor: 4.530

6.  Patterns of drug use, risky behavior, and health status among persons who inject drugs living in San Diego, California: a latent class analysis.

Authors:  Alexis M Roth; Richard A Armenta; Karla D Wagner; Scott C Roesch; Ricky N Bluthenthal; Jazmine Cuevas-Mota; Richard S Garfein
Journal:  Subst Use Misuse       Date:  2014-10-14       Impact factor: 2.164

7.  Prevalence and Correlates of Heroin-Methamphetamine Co-Injection Among Persons Who Inject Drugs in San Diego, California, and Tijuana, Baja California, Mexico.

Authors:  Meredith C Meacham; Steffanie A Strathdee; Gudelia Rangel; Richard F Armenta; Tommi L Gaines; Richard S Garfein
Journal:  J Stud Alcohol Drugs       Date:  2016-09       Impact factor: 2.582

Review 8.  Cognitive behavioral theories used to explain injection risk behavior among injection drug users: a review and suggestions for the integration of cognitive and environmental models.

Authors:  Karla Dawn Wagner; Jennifer B Unger; Ricky N Bluthenthal; Valentina A Andreeva; Mary Ann Pentz
Journal:  Health Educ Behav       Date:  2010-08

9.  Developing an HIV behavioral surveillance system for injecting drug users: the National HIV Behavioral Surveillance System.

Authors:  Amy Lansky; Abu S Abdul-Quader; Melissa Cribbin; Tricia Hall; Teresa J Finlayson; Richard S Garfein; Lillian S Lin; Patrick S Sullivan
Journal:  Public Health Rep       Date:  2007       Impact factor: 2.792

10.  HIV prevalence and risk among heterosexual methamphetamine injectors in California.

Authors:  Alex H Kral; Jennifer Lorvick; Alexis Martinez; Megan A Lewis; W Alexander Orr; Rachel Anderson; Neil Flynn; Ricky N Bluthenthal
Journal:  Subst Use Misuse       Date:  2011-03-10       Impact factor: 2.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.